(Reuters) -The U.S. Food and Drug Administration has approved the use of Novartis’ drug to reduce excess protein in the urine of patients with a type of kidney disease, the health regulator’s website showed on Wednesday.
The drug, Fabhalta, is already approved to treat adults with paroxysmal nocturnal hemoglobinuria, a rare blood disorder.
With the expanded approval, Novartis’ drug entered the IgA nephropathy market and will compete with Swedish drugmaker Calliditas’ Tarpeyo and Travere Therapeutics’ Filspari.
Guggenheim analyst Vamil Divan sees the IgAN market valuing at $10 billion over time as more treatments comes to market.
IgAN occurs when clumps of antibodies are deposited in kidneys, causing inflammation that damages its tiny filtering units.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
Comments